Telix Pharmaceuticals Limited

12 articles with Telix Pharmaceuticals Limited

• Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

  9/24/2020

  Telix Pharmaceuticals Limited announces it has submitted a New Drug Application to the United States Food and Drug Administration for TLX591-CDx, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.1

• Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging - Sep 03, 2020

  9/3/2020

  Telix Pharmaceuticals Limited announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform.

• ARTMS Announces New Appointments to Executive Leadership TeamCompany adds experienced executives to support the continued expansion of commercial activities and focus on radiopharmaceutical innovator and manufacturer relationships

  9/2/2020

  ARTMS Inc., the global leader in the development and commercialization of technologies that are transforming the production of the world’s most-used diagnostic imaging isotopes, announced that it has expanded its senior management team with the addition of two industry veterans, Doug Gentilcore as Chief Commercial Officer and Mark Przekop as Vice President of Marketing and Business Development.

• RefleXion and Telix Pharmaceuticals Announce Strategic Collaboration for Treatment of High-Risk Cancers

  7/8/2020

  RefleXion Medical , a therapeutic oncology company pioneering biology-guided radiotherapy* ( BgRT ) as a new modality for treating all stages of cancer, and Telix Pharmaceuticals Limited (ASX: TLX), a radiopharmaceutical company developing molecularly-targeted radiation ( MTR ) products, today announced a strategic collaboration to investigate the clinical utility of combining the companies’

• ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration

  5/6/2020

  ARTMS Products Inc . (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, and Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) announced today they have entered into a development

• Heidelberg Pharma Receives Milestone Payment from Partner Telix

  6/5/2019

  Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.

• Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging

  10/3/2018

  Telix Pharmaceuticals (US) Inc. today announced that it has entered into a distribution agreement with Cardinal Health (NYSE:CAH).

• Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe

  8/23/2018

  Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).

• Telix and Nihon Medi-Physics to Collaborate on Renal Cancer Imaging for the Japanese Market

  8/15/2018

  Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.

• First Patient Imaged in Prostate Imaging Study

  8/12/2018

  Telix Pharmaceuticals Limited is pleased to announce that Memorial Sloan Kettering Cancer Center (“MSK”) has imaged the first two patients in a 500 patient Phase II Expanded-Access Investigational New Drug (IND) study for imaging prostate cancer with the investigational agent 68Ga-PSMA-11

• Telix and Isologic conclude manufacturing agreement for North America

  6/25/2018

  Telix Pharmaceuticals Limited has announced a technology transfer and manufacturing agreement with ISOLOGIC Innovative Radiopharmaceuticals

• 

  Telix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives

  1/15/2018

  The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products.